Objective      To investigate the relationship of serum urokinase-type plasminogen activator receptor (uPAR) with chemosensitivity and prognosis in patients with small cell lung cancer (SCLC).       Methods      The serum levels of uPAR were detected in 80 patients with SCLC before and after chemotherapy using enzyme-linked immunosorbent assay (ELISA).       Results      The serum levels of uPAR significantly decreased in the SCLC patients after chemotherapy (P0.05). Kapan-Meier analysis showed that the uPAR level was significantly correlated with the prognosis of the SCLC patients (P0.05). The median survival time was 13.3 months in the SCLC patients with high uPAR levels (2.057 μg/L)

and was 21.5 months in the SCLC patients with low uPAR levels (≤2.057 μg/L). Cox model analysis showed that uPAR might be an independent prognostic factor to determine the patients’ survival time (P0.05).       Conclusion      The elevated serum level of uPAR may indicate poor prognosis of SCLC

and the uPAR expression level may be used as an indicator to evaluate the chemotherapy sensitivity in SCLC patients.